id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2001-E-0148-0002,FDA,FDA-2001-E-0148,Letter from Associate Director for Policy Center for Drug Evaluation and Research to  U.S. Patent and Trademark Office,Other,Letter(s),2003-07-28T04:00:00Z,2003,7,,,2025-10-10T00:20:29Z,,0,0,09000064804ddca7
FDA-2001-E-0148-0001,FDA,FDA-2001-E-0148,"Determination of Regulatory Review Period for Purposes of Patent
Extension; ACOVA",Notice,General Notice,2002-11-14T05:00:00Z,2002,11,2002-11-14T05:00:00Z,2003-01-14T04:59:59Z,2025-10-10T00:02:57Z,,0,0,09000064804ddc99